Literature DB >> 15868406

Congenital muscular dystrophy: molecular and cellular aspects.

C Jimenez-Mallebrera1, S C Brown, C A Sewry, F Muntoni.   

Abstract

The congenital muscular dystrophies are a clinically and genetically heterogeneous group of neuromuscular disorders. Each form has a characteristic phenotype, but there is overlap between some entities and their classification is based on a combination of clinical features and the primary or secondary protein defect. Recent studies have identified the genetic basis of a number of congenital muscular dystrophies (11 genes in total) and have recognised a novel pathological mechanism that highlights the importance of the correct posttranslational processing of proteins, in particular alpha-dystroglycan. Diagnosis of these conditions has been aided by the availability of specific antibodies for each protein and a better understanding of the protein changes that accompany each condition. In this review we present the major molecular, clinical and diagnostic aspects of each group of congenital muscular dystrophy with an emphasis in the more recent developments.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15868406     DOI: 10.1007/s00018-004-4510-4

Source DB:  PubMed          Journal:  Cell Mol Life Sci        ISSN: 1420-682X            Impact factor:   9.261


  48 in total

1.  RPTPζ/phosphacan is abnormally glycosylated in a model of muscle-eye-brain disease lacking functional POMGnT1.

Authors:  C A Dwyer; E Baker; H Hu; R T Matthews
Journal:  Neuroscience       Date:  2012-06-19       Impact factor: 3.590

Review 2.  Immunobiology of Inherited Muscular Dystrophies.

Authors:  James G Tidball; Steven S Welc; Michelle Wehling-Henricks
Journal:  Compr Physiol       Date:  2018-09-14       Impact factor: 9.090

Review 3.  Extracellular matrix: The driving force of mammalian diseases.

Authors:  Renato V Iozzo; Maria A Gubbiotti
Journal:  Matrix Biol       Date:  2018-04-03       Impact factor: 11.583

4.  Synthetic, structural, and biosynthetic studies of an unusual phospho-glycopeptide derived from α-dystroglycan.

Authors:  Kai-For Mo; Tao Fang; Stephanie H Stalnaker; Pamela S Kirby; Mian Liu; Lance Wells; Michael Pierce; David H Live; Geert-Jan Boons
Journal:  J Am Chem Soc       Date:  2011-08-22       Impact factor: 15.419

Review 5.  The nature and biology of basement membranes.

Authors:  Ambra Pozzi; Peter D Yurchenco; Renato V Iozzo
Journal:  Matrix Biol       Date:  2016-12-28       Impact factor: 11.583

Review 6.  The dystroglycanopathies: the new disorders of O-linked glycosylation.

Authors:  Paul T Martin
Journal:  Semin Pediatr Neurol       Date:  2005-09       Impact factor: 1.636

7.  Laminin-111 restores regenerative capacity in a mouse model for alpha7 integrin congenital myopathy.

Authors:  Jachinta E Rooney; Praveen B Gurpur; Zipora Yablonka-Reuveni; Dean J Burkin
Journal:  Am J Pathol       Date:  2008-12-12       Impact factor: 4.307

8.  Muscular dystrophy associated with alpha-dystroglycan deficiency in Sphynx and Devon Rex cats.

Authors:  Paul T Martin; G Diane Shelton; Peter J Dickinson; Beverly K Sturges; Rui Xu; Richard A LeCouteur; Ling T Guo; Robert A Grahn; Harriet P Lo; Kathryn N North; Richard Malik; Eva Engvall; Leslie A Lyons
Journal:  Neuromuscul Disord       Date:  2008-11-05       Impact factor: 4.296

9.  Biochemical and biophysical changes underlie the mechanisms of basement membrane disruptions in a mouse model of dystroglycanopathy.

Authors:  Peng Zhang; Yuan Yang; Joseph Candiello; Trista L Thorn; Noel Gray; Willi M Halfter; Huaiyu Hu
Journal:  Matrix Biol       Date:  2013-02-27       Impact factor: 11.583

10.  B4GALNT2 (GALGT2) Gene Therapy Reduces Skeletal Muscle Pathology in the FKRP P448L Mouse Model of Limb Girdle Muscular Dystrophy 2I.

Authors:  Paul J Thomas; Rui Xu; Paul T Martin
Journal:  Am J Pathol       Date:  2016-09       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.